A new article highlights MAIA's THIO-101 Phase 2 trial expansion, with the first patient now dosed in Taiwan for 3L #NSCLC. Key takeaway: Early ateganosine (THIO) data shows a median OS of 17.8 months. Read more @TrialsArena: $MAIA.

MAIA Biotechnology Announced Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy. Read the press release: . $MAIA #Biotech #Oncology #ClinicalResearch

"Ateganosine’s observed OS in third-line #NSCLC exceeds all known benchmarks.” – Dr. Vlad Vitoc, MAIA CEO. See announcement on our Phase 2 trial expansion: . $MAIA #Biotech #Oncology

MAIA recently announced THIO-101 trial data for advanced #NSCLC, with median OS of 17.8 months for third-line patients, exceeding known benchmarks. This positions a potential first-mover advantage in a multi-billion-dollar space. $MAIA #Immunotherapy.

ICYMI: MAIA has dosed the first patient in Taiwan for the expansion phase of its THIO-101 Phase 2 trial for advanced #NSCLC. This marks a key milestone, opening a significantly larger patient pool for evaluation of ateganosine (THIO). $MAIA #Biotechnology

MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer. Read the press release: . $MAIA #Biotech #NSCLC

MAIA is presenting two posters today at the #FEBS2025Congress, Cancer Therapy session, 12:30-2:30pm TRT, highlighting our lead telomere-targeting agent and next-generation treatments. Poster presentation details available here: $MAIA

MAIA will present two posters at #FEBSCongress2025 featuring our lead telomere-targeting agent and next-generation treatments. Session date and time: July 7, 2025, from 12:30pm to 2:30pm TRT. More details are available here: . $MAIA #Oncology #Biotech

MAIA Biotechnology to present two posters featuring cancer telomere-targeting agents at @FEBSnews. Read the press release: . $MAIA #FEBSCongress2025 #CancerResearch #Oncology #Biotech

MAIA's clinical master supply agreement with Roche supports the evaluation of ateganosine (THIO) in combination with Tecentriq® in hard-to-treat cancers. The combination was found to be highly synergistic and effective in #preclinical studies. ICYMI: $MAIA.

MAIA is planning for a Phase 2 clinical trial in #hepatocellularcarcinoma. With the appointment of our new SAB members, they will advise MAIA on designs and protocols for its CST in HCC and may participate in future investigator sponsored trials. $MAIA

MAIA’s CEO Dr. Vlad Vitoc explains how we're advancing oncology with our lead molecule ateganosine, now initiating pivotal trials for #NSCLC after Phase II results. Read how we're positioned in today's #biotech market: $MAIA #ClinicalTrials #Oncology.

MAIA Biotechnology is pleased to welcome leading #hepatocellularcarcinoma clinician-scientists to its Scientific Advisory Board. Planning for phase 2 #clinicaltrial in HCC underway. Read the press release: . $MAIA #Oncology #Biotech

MAIA is pleased to announce a master clinical supply agreement with Roche for hard-to-treat cancer therapies. Read the press release: . $MAIA #Immunotherapy #Oncology #Biotech

Today, MAIA will highlight the latest findings from our THIO-101 Phase 2 clinical trial in #NSCLC at #BIO2025 at 11:30 AM EDT. More on our CEO’s presentation: $MAIA #Biotech #Oncology

MAIA is looking forward to presenting at #BIO2025 tomorrow at 11:30 AM EDT. CEO Vlad Vitoc, MD, MBA, will present data from the THIO-101 Phase 2 trial in advanced #NSCLC. Request a meeting with MAIA management: . $MAIA #Biotech

MAIA’s CEO is presenting at #BIO2025 on 6/18 at 11:30 AM EDT to present the latest findings from the THIO-101 Phase 2 clinical trial evaluating ateganosine (THIO) sequenced with the immune CPI cemiplimab (Libtayo®) in advanced #NSCLC. $MAIA

MAIA Biotechnology to Present at BIO International Convention 2025 taking place June 16-19, 2025, in Boston, Massachusetts. Presentation details are available in the press release: $MAIA #BIO2025 @IAmBiotech

MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial. Read the press release here: $MAIA #Biotech #NSCLC

MAIA announces positive efficacy update for Phase 2 THIO-101 #clinicaltrial in #NSCLC. Read the press release: $MAIA #Biotech